Original Article

You have full text access to this OnlineOpen article

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

How does it relate to the original lenalidomide experience in MDS?

  1. Hagop Kantarjian MD1,†,*,
  2. Susan O'Brien MD1,
  3. Farhad Ravandi MD1,
  4. Gautam Borthakur MD1,
  5. Stefan Faderl MD1,
  6. Carlos Bueso-Ramos MD2,
  7. Lynne Abruzzo MD2,
  8. Sherry Pierce RN1,
  9. Jianqin Shan PhD1,
  10. Jean-Pierre Issa MD1,
  11. Guillermo Garcia-Manero MD1

Article first published online: 18 AUG 2009

DOI: 10.1002/cncr.24575

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5202–5209, 15 November 2009

Additional Information

How to Cite

Kantarjian, H., O'Brien, S., Ravandi, F., Borthakur, G., Faderl, S., Bueso-Ramos, C., Abruzzo, L., Pierce, S., Shan, J., Issa, J.-P. and Garcia-Manero, G. (2009), The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities. Cancer, 115: 5202–5209. doi: 10.1002/cncr.24575

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 794-4297

*Department of Leukemia, Box 428, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 18 AUG 2009
  3. Manuscript Accepted: 31 DEC 2008
  4. Manuscript Revised: 23 DEC 2008
  5. Manuscript Received: 17 NOV 2008

Funded by

  • Leukemia SPORE. Grant Numbers: 1P50CA100632-04, PO1CA108631
  • National Institutes of Health National Cancer Institute

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (398K)

References

  • 1
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Heamatol. 1982; 51: 189-199.
  • 2
    Harris NJ, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia: November 1977. J Clin Oncol. 1999; 17: 3835-3849.
  • 3
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
  • 4
    Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer. 2008; 113: 1351-1361.
    Direct Link:
  • 5
    Faderl S. Kantarjian H. Myelodysplastic Syndromes. In: DeVita V, Lawrence T, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: 2292-2303.
  • 6
    Nimer S, Golde D. The 5q-abnormality. Blood. 1987; 70: 1705-1712.
  • 7
    Nimer S. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. JCO. 2006; 24: 2576-2582.
  • 8
    Giagounidis AAN, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004; 18: 113-119.
  • 9
    Mathew P, Tefferi A, Dewald GW, et al. The 5q- syndrome: A single-institution study of 43 consecutive patients. Blood. 1993; 81: 1040-1045.
  • 10
    Cermak J, Michalova K, Brezinova J, et al. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res. 2003; 27: 221-229.
  • 11
    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465.
  • 12
    European Medicines Agency. Assessment report for lenalidomide Celgene Europe. London: 2008. Document reference EMEA/CHMP/249329/2008.
  • 13
    Gohring G, Giagounidis A, Aul C, et al. Long-term cytogenetic follow-up of MDS patients with 5q- treated within the MDS-003 (CC-5013-MDS-003) study: evolution to complex clones and progression to AML [abstract]. Blood. 2008; 112. Abstract 1647.
  • 14
    Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006; 108: 1835-1840.
  • 15
    Roy L, Guilhot J, Krahnke T, et al. Survival advantage from Imatinib compared to the combination Interferon-α plus Cytarabine in chronic phase CML: historical comparison between two phase III trials. Blood. 2006; 108: 1478-1484.
  • 16
    del Mar Mallo M, Cervera J, Schanz J, et al. Prognostic impact of additional chromosomal aberrations (ACA) to 5q- in patients with primary myelodysplastic syndrome [abstract]. Blood. 2008; 112( S1). Abstract 1649.
  • 17
    Holtan S, Santana-Davila R, DeWald G, et al. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era. Am J Hematol. 2008; 83: 708-713.
    Direct Link:
View Full Article (HTML) Get PDF (398K)